The reasons for the stop of the Italian anti-Covid Reithera vaccine have been filed. The investment for the ReiThera project cannot include the purchase of the ownership of the Company’s operational headquarters, located in Castel Romano, while the expenditure for the construction of the filling and packaging plant alone for the Reithera vaccine project would amount to 7.734 million. euro and would not reach the minimum threshold of 10 million euro provided for by the regulations, says the Court of Auditors explaining the reasons that led to the refusal of the visa to the decree of the Ministry of Economic Development which approved the Agreement of February 2021, which involved also Invitalia and ReiThera, “aimed at supporting the industrial development program to be implemented at the production plant located in Castel Romano”. The Court recalls how “this program included an investment project aimed at expanding the production plant located in Castel Romano and an industrial research and experimental development project intended to complete the clinical trial (phase 2 and 3 clinical trials) of the anti-vaccine COVID-19”. But the competent Section “considered the proposed investment project irreconcilable with the condition set by art. 15, paragraph 1, of the Ministerial Decree of 9 December 2014, according to which the expenses are admissible to the extent necessary for the purposes of the project object of and not, as shown by the project presented, for the general purposes – production or research, also on behalf of third parties – pursued by ReiThera, nor for the even more general purposes of strengthening the equity consistency of the company “. For the accounting magistrates “the productive investment project, in fact, cannot concern the entire company complex but only certain ‘production units'”.